Inventor
VAHLNE ANDERS
SE21 patents
⚠️ This page may combine multiple inventors who share the name “VAHLNE ANDERS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TRIPEP AB
9 patentsUS6258932B1Jul 10, 2001
Peptides that block viral infectivity and methods of use thereof
TRIPEP AB31 citations92
US7318926B2Jan 15, 2008
Glycosylated specificity exchangers
TRIPEP AB10 citations91
US6455670B1Sep 24, 2002
Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof
TRIPEP AB14 citations86
US7332166B2Feb 19, 2008
Glycosylated specificity exchangers
TRIPEP AB6 citations72
US7012129B2Mar 14, 2006
Antiviral composition comprising glycine amide
TRIPEP AB8 citations71
US7534435B2May 19, 2009
Glycosylated specificity exchangers
TRIPEP AB4 citations61
US7335359B2Feb 26, 2008
Glycosylated specificity exchangers
TRIPEP AB1 citations51
US6593455B2Jul 15, 2003
Tripeptide amides that block viral infectivity and methods of use thereof
TRIPEP AB0 citations46
US6537967B1Mar 25, 2003
Pentamer peptide amide, ALGPGNH2, which inhibits viral infectivity and methods of use thereof
TRIPEP AB0 citations46
SYNTELLO VACCINE DEV KB
4 patentsUS5840313ANov 24, 1998
Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
SYNTELLO VACCINE DEV KB60 citations92
US5627035AMay 6, 1997
Peptides that block human immunodeficiency virus and methods of use thereof
SYNTELLO VACCINE DEV KB25 citations90
US5589175ADec 31, 1996
Peptides for induction of neutralizing antibodies against human immunodeficiency virus
SYNTELLO VACCINE DEV KB12 citations71
US5346989ASep 13, 1994
Peptides for use in induction of T cell activation against HIV-1
SYNTELLO VACCINE DEV KB15 citations71